Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma. (Q33501572)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9457812%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

title

Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9457812%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9457812%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

author name string

J C Buckner

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9457812%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

P J Schomberg

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9457812%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

T L Cascino

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9457812%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

P A Burch

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9457812%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

R P Dinapoli

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9457812%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

language of work or name

English

0 references

publication date

1 January 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9457812%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Radiation Oncology Biology Physics

9 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9457812%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

volume

40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9457812%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9457812%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

297-302

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9457812%20AND%20SRC:MED&resulttype=core&format=json

Interferons in the therapy of solid tumors

9 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900739-6

7 January 2021

Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900739-6

7 January 2021

Medical treatment of advanced renal cell carcinoma: present options and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900739-6

7 January 2021

Brief communication: Cure of murine leukemia with drug and interferon treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900739-6

7 January 2021

Phase I study of recombinant leukocyte A human interferon combined with BCNU in selected patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900739-6

7 January 2021

Interferon alpha-2a and external beam radiotherapy in the initial management of patients with glioma: a pilot study of the National Biotherapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900739-6

7 January 2021

The basis for current treatment recommendations for malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900739-6

7 January 2021

Novel biologic therapies for malignant gliomas. Antiangiogenesis, immunotherapy, and gene therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900739-6

7 January 2021

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900739-6

7 January 2021

Addition of IFN-alpha to treatment of malignant brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900739-6

7 January 2021

Advantage of Post-Radiotherapy Chemotherapy with CCNU, Procarbazine, and Vincristine (mPCV) Over Chemotherapy with VM-26 and CCNU for Malignant Gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900739-6

7 January 2021

Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900739-6

7 January 2021

A phase II evaluation of human lymphoblastoid interferon (Wellferon) in relapsed high grade malignant glioma. Medical Research Council Brain Tumour Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900739-6

7 January 2021

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900739-6

7 January 2021

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2897%2900739-6

7 January 2021

10.1016/S0360-3016(97)00739-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9457812%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference